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The authors would like to make the following corrections to their published paper: 
There was an error in calculation of IC50 fold changes for the NAI-resistant viruses reported in 
Table 1 of the above-mentioned paper. The corrected values are marked in the updated Table 1 below.  
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Table 1. Reference viruses used as controls in the chemiluminescent NI Assay. 






b, nM (Fold Difference
 c) 
Oseltamivir  Zanamivir  Peramivir 
A/Washington/10/2008  A (H1N1); Seasonal  WT
d  S
e  0.23±0.07 (1)  0.24±0.08 (1)  0.09±0.02 (1) 
A/Florida/21/2008  A (H1N1); Seasonal  H275Y  R
f  94.82±27.04 
(386412)  0.31±0.08 (1)  11.27±1.36 
(134125) 
A/Washington/01/2007  A (H3N2); Seasonal  WT  S  0.15±0.00 (1)  0.47±0.04 (1)  0.12±0.02 (1) 
A/Texas/12/2007  A (H3N2); Seasonal  E119V  R  4.19±0.33 (3028)  0.51±0.05 (1)  0.14±0.02 (1) 
B/Memphis/20/1996  B; Seasonal  WT  S  1.61±0.21 (1)  1.94±0.21 (1)  0.31±0.06 (1) 




A/California/07/2009  H1N1; Pandemic  WT  S  0.21±0.03 (1)  0.26±0.04 (1)  0.06±0.02 (1) 
A/Texas/48/2009  H1N1; Pandemic  H275Y  R  79.94±0.06 
(348381)  0.36±0.07 (1)  10.06±0.01 
(164168) 
a Average of 3 independent assays. 
b SD, Standard Deviation of IC50 values. 
c Fold difference in IC50 values between mutant and wildtype viruses, by drug 
and virus type/subtype (IC50 of mutant/IC50 of wildtype virus). 
d WT, Wildtype. 
e S, Sensitive (Susceptible). 
f R, Resistant. 
 
We apologize for any inconvenience caused to the readers. 
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